Claret Capital Bets €43M on Inventiva's Bid to Conquer Liver Disease

LONDON, UK – June 16, 2026 – In a significant move underscoring confidence in European biotechnology, Claret Capital Partners has committed €43 million to French biopharmaceutical firm Inventiva. The investment is a key part of a broader €130 million debt financing package, co-led with funds managed by BlackRock, designed to propel Inventiva's lead drug candidate, lanifibranor, through its final and most critical phase of clinical trials. This strategic capital infusion targets one of modern medicine's most formidable challenges: metabolic dysfunction-associated steatohepatitis (MASH), a severe and progressive liver disease affecting millions worldwide. The deal not only provides Inventiva with a crucial financial runway but also spotlights an evolving strategy for funding late-stage life science companies in a capital-intensive industry.

A Strategic Infusion for a Pivotal Trial

The financing structure is a masterclass in strategic growth management. By utilizing growth debt, Inventiva secures substantial capital without diluting the ownership of its existing shareholders—a critical consideration for a publicly traded company on the cusp of a major value inflection point. This non-dilutive approach is increasingly vital for biotechs navigating the so-called “valley of death” of late-stage clinical development, where costs for Phase 3 trials can run into the hundreds of millions.

Claret Capital, Europe's largest independent growth debt fund manager, specializes in this type of sophisticated financial support. Joey Mason, Life Sciences Venture Partner at Claret, highlighted the strategic fit, stating, “This investment demonstrates the type of support we can provide to late stage biotechs - even listed ones - with exciting assets who need the firepower to get them to the next stage.”

The timing is paramount. The funds are earmarked to support Inventiva through its NATiV3 Phase 3 trial, with top-line results anticipated in the fourth quarter of 2026. This provides the company with a clear financial runway to reach its next major clinical milestone. “This financing provides additional flexibility as Inventiva moves towards anticipated key clinical and regulatory milestones in 2026 and 2027,” commented Daniel Mallon, Principal at Claret Capital.

For Inventiva, the deal is about more than just cash; it's about securing a position of strength ahead of a defining moment. Andrew Obenshain, Chief Executive Officer of Inventiva, framed the transaction as a proactive move based on deep conviction in the drug's potential. “With this transaction, we believe Inventiva will be well-positioned, scientifically, operationally, and financially, to lead our program through anticipated defining milestones and beyond,” he said. “This transaction is a direct expression of that confidence, implementing a proactive strategy designed to ensure Inventiva enters this critical clinical moment from a position of strength.”

Targeting a Silent Epidemic

MASH is a silent but escalating global health crisis. Characterized by fat accumulation, inflammation, and scarring (fibrosis) in the liver, the disease can progress to cirrhosis, liver failure, and cancer. It currently affects over 250 million people worldwide, many of whom are undiagnosed, and is projected to become the leading cause of liver transplants for women in the United States. The rise of obesity and metabolic syndrome has fueled its prevalence, creating a vast and largely underserved patient population.

The MASH treatment landscape has recently seen long-awaited breakthroughs with the FDA approvals of Madrigal Pharmaceuticals' Rezdiffra (resmetirom) and Novo Nordisk's Wegovy (semaglutide). While these approvals have validated the market and offered hope to patients, they have also highlighted the complexity of the disease and the need for diverse therapeutic options.

This is where Inventiva's lanifibranor aims to carve out its niche. The drug is a first-of-its-kind pan-PPAR (peroxisome proliferator-activated receptor) agonist, meaning it simultaneously activates all three PPAR isoforms—alpha, delta, and gamma. This unique mechanism of action allows it to comprehensively target the multifaceted pathology of MASH: PPAR-alpha activation helps modulate lipid metabolism, PPAR-delta activation improves insulin sensitivity, and PPAR-gamma activation helps control inflammation and fibrogenesis. By addressing the metabolic, inflammatory, and fibrotic pathways all at once, lanifibranor holds the potential to be a more holistic treatment, a key differentiator in an increasingly competitive field.

Claret Capital's Expanding Bet on European Life Sciences

This investment is not an isolated event but rather a clear signal of Claret Capital’s overarching strategy. The firm has steadily been increasing its activity in the European life sciences sector, backing promising late-stage companies with the capital needed to cross the finish line. Recent investments in Sweden’s Cinclus Pharma, which is developing a treatment for GERD, and France’s Abivax, focused on inflammatory diseases, reveal a pattern of identifying and supporting European leaders.

The Inventiva deal reinforces this trend, showcasing a maturing European biotech ecosystem where local capital can fuel globally competitive innovation. The ability for a French biotech to secure significant financing from a European-led syndicate demonstrates a growing self-sufficiency, reducing reliance on traditionally dominant US capital markets and fostering a stronger, more resilient continental life sciences hub.

Navigating the High-Stakes Path to Market

The newly secured financing provides Inventiva the resources to navigate the final, high-stakes leg of its journey. All eyes in the hepatology and investment communities are now fixed on the fourth quarter of 2026, when the top-line results from the NATiV3 Phase 3 trial are expected. The MASH development space is notoriously challenging—often referred to as a “graveyard” for its high rate of late-stage trial failures—which makes this robust financial backing all the more critical.

Adding to the optimism, lanifibranor has already received both Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration (FDA). While not a guarantee of success, these designations acknowledge the drug's potential to address a serious unmet need and could help expedite the regulatory review process should the Phase 3 data prove positive. The outcome of the trial will not only shape Inventiva's future but also has the potential to introduce a powerful new weapon in the global fight against a devastating chronic liver disease.